HIV mutation literature information.


  Persistence of Human Immunodeficiency Virus-1 Drug Resistance Mutations in Proviral Deoxyribonucleic Acid After Virologic Failure of Efavirenz-Containing Antiretroviral Regimens.
 PMID: 30863788       2019       Open forum infectious diseases
Method: Nucleoside reverse-transcriptase inhibitor DRMs included M41I/L, D67N/E, K70R, M184V, T215Y/F/C/S, K219Q/E; NNRTI DRM included K103N, Y181C, G190A/S/R, L100I, K101E, V106I/M, Y188H/C/L, M230I/L.


  Prevalence and persistence of transmitted drug resistance mutations in the German HIV-1 Seroconverter Study Cohort.
 PMID: 30650082       2019       PloS one
Result: A Kaplan-Meier analysis could be performed for 18 TDRMs (K20T, L23I, K43T, M46I/L/V, I54V, M41L, L74I, M184V, L210W, K219R, T215A/C/D/N/S and T215Y).
Result: The presence of three or more TDRMs was mainly due to the accumulation of Thymidine-Analogue-Mutations (TAMs: M41L, D67N, K70R, L210W, T215F/Y, T215 revertants and K21


  Drug resistance evolution in patients with human immunodeficiency virus-1 under long-term antiretroviral treatment-failure in Yunnan Province, China.
 PMID: 30621727       2019       Virology journal
Abstract: M184 V/I (26.14%), T69S (11.36%), and T215Y/I (10.23%) mutations were the most common in nucleoside reverse transcriptase inhibitors (NRTIs), and K103 N/R/S (21.59%), V179D/E (20.45%) in Non-NRTIs (NNRTIs).
Result: The most common NRTIs mutations were M184 V/I,
Discussion: Two clusters were studied here; TAM-1 (M41 L and T215Y) and TAM-2 (D67N, K70R, and K219Q).


  Virological outcomes of boosted protease inhibitor-based first-line ART in subjects harbouring thymidine analogue-associated mutations as the sole form of transmitted drug resistance.
 PMID: 30544247       2019       The Journal of antimicrobial chemotherapy
Abstract: Most (203 of 269, 75.5%) had singleton TAMs, commonly a revertant of T215Y or T215F (112 of 269, 41.6%).
Introduction: More recently, investigators at Gilead Sciences merged data from a variety of clinical trials and reported that virological responses to 48 weeks of tenofovir-based first-line regimens were not diminished among 205 patients harbouring >=1 TAM, including 76 subjects with revertants of T215Y or T215F (T215rev.
Method: TAMs comprised the RT mutations M41L, D67N/G/E, K70R, L210W, T215Y/F/rev and


  Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay.
 PMID: 30409215       2018       AIDS research and therapy
Result: Most of these minority drug resistance mutations were detected in the 67 cART-experienced individuals, e.g., the HIV-1 genotype of the following patients consisted of a mixture of majority and minority drug resistance mutations: patient SG79 (PR V11I 99.9%, K20I 99.9%; RT E44D 1.3%, D67N 1.1%, L100I 1.7%, M184V 84.9%, M184I 14.8%, K219Q 2.1%, INT E157Q 99.8%), patient SG86 (RT M184V 99.8%, INT L74M 97.9%, L74I 1.9%, E92Q 86


  Resistance profile of children and adolescents infected with HIV-1 in urban areas in Togo.
 PMID: 30799830       2018       Medecine et sante tropicales
Abstract: The mutations associated with the most frequent NRTIs were M184V, Y181C, and T215Y.


  Molecular Antiretroviral Resistance Markers of Human Immunodeficiency Virus-1 of CRF01_AE Subtype in Bali, Indonesia.
 PMID: 30714528       2018       Current HIV research
Discussion: Molecular marker mutations in more than 50% of treatment failure patients were M184V, T215A/Y/F, D67N/G, and M41L.
Discussion: Molecular markers of TAMs, M184V (100%), T215A/Y/F (88.2%), D67N/G (76.5%), and M41L (58.8%), were found in more than 50% of treatment failure patients.
Discussion: There are two clusters of TAMs; cluster 1 includes substitutions of M41L, L210W and T215Y, while cluster 2 of D67N, K70R, T125F and


  Risk factors and outcomes for the Q151M and T69 insertion HIV-1 resistance mutations in historic UK data.
 PMID: 29661246       2018       AIDS research and therapy
Result: Thymidine analogue mutations (TAMs) were most frequently seen, with TAM1 mutations (M41L, L210W and T215Y) being most common.
Table: T215Y/F


  Impact of Antiretroviral Regimens on Cerebrospinal Fluid Viral Escape in a Prospective Multicohort Study of Antiretroviral Therapy-Experienced Human Immunodeficiency Virus-1-Infected Adults in the United States.
 PMID: 29617912       2018       Clinical infectious diseases
Result: Given the high frequency of M184V/I detected in all samples (28%, 56/197), these mutations were combined with thymidine-analog mutations (TAMs; ie, M41L, L210W, T215Y, D67N, K70R, T215F, K219Q/E) for analysis.


  Prevalence of M184V and K65R in proviral DNA from PBMCs in HIV-infected youths with lamivudine/emtricitabine exposure.
 PMID: 29084434       2018       AIDS research and human retroviruses
Introduction: However, in the 31 patients with no K65R present at S2, 6 had intermediate or high-level resistance to AZT: 4 were caused by TAM-2 DRMs, 1 by T215Y, and 1 by Q151M-complex mutations Q151M, A62V, V75I, F77L, F116Y.
Introduction: In viruses lacking K65R, the TAMs observed included a broader array of primarily TAM-2, including K219E, D67N, K70R, T215F, and K219Q, and in one patient with TAM-1, T215Y.



Browser Board

 Co-occurred Entities




   Filtrator